Redcare Pharmacy stock faces valuation upside and execution risks

On Wednesday, November 11, Simply Wall St described Redcare Pharmacy's stock as a balance between valuation upside and execution risk. Its analysis points to the company's confirmed 2026 revenue-growth outlook of 16% to 18% while questioning how much optimism is already reflected in the share price. The Simply Wall St analysis links the valuation debate to Redcare's nine-month performance and its unchanged guidance.

The analysis places fair value at 88.8 euros, compared with a last close of 73.65 euros. That estimate is based on a discounted cash-flow approach using a 5.48% discount rate and long-term earnings and revenue forecasts. The gap supports a constructive valuation argument, but it does not remove the need for stronger operating delivery.

Growth must convert into margins

Simply Wall St highlights the potential contribution from Redcare's logistics investments. The new Pilsen center and the Sevenum automation project are expected to improve fulfillment efficiency, with the analysis citing a target of up to 70% lower labor cost per order and additional capacity from 2027. Those projects could support adjusted EBITDA margins and net income if implementation proceeds as planned.

The valuation picture is less favorable when measured against sales. Redcare trades at a price-to-sales ratio of 0.5 times, according to the analysis, versus 0.6 times for comparable companies. Its own estimated fair ratio is 0.1 times, showing that the shares still depend on investors accepting a premium to the model's sales-based benchmark.

The principal risks are tied to execution rather than the headline revenue target. Less favorable prescription rules in Germany or elsewhere in Europe could weaken demand, while stronger competition in non-prescription products could require higher marketing spending and pressure margins. The analysis also warns that logistics delays would reduce the expected efficiency benefits.

Redcare Pharmacy stock traded at 72.85 euros on Lang & Schwarz at 11:34 CET on Wednesday, November 11, 2026, 1.09 percent below the Xetra close of Tuesday, November 10, at 73.65 euros. The quote places the shares below the analysis's fair-value estimate, but the intraday move alone does not establish a cause.

The broader Dutch equity market can be followed through the AEX market environment.

For more context, see More news and analyses on Redcare Pharmacy stock.